Clinical Trials Logo

Clinical Trial Summary

This is a single arm, open-label, single-center, phase 1/2 study, to determine the safety and efficacy of TriCAR-T-CD19, an autologous tri-functional anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory/Relapsed Non-Hodgkin Lymphoma (NHL).

Clinical Trial Description

The tri-functional anti-CD19 chimeric antigen receptor contains an anti-CD19 scFv, a PD-L1 blocker, and a cytokine complex, enabling the TriCAR-T-CD19 to simultaneously targeting the CD19 positive NHL´╝îblocking the inhibitory PD-L1 signal and stimulating T/NK cell activation and expansion. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03497533
Study type Interventional
Source Timmune Biotech Inc.
Contact Ming Zhou
Phone +86 0731 83928147
Status Recruiting
Phase Phase 1/Phase 2
Start date August 3, 2018
Completion date December 31, 2020